Chr. Hansen HMO v. Glycosyn: 2′-FL HMO Patent Dispute Settled With Prejudice
Chr. Hansen HMO GmbH filed a declaratory judgment action against Glycosyn LLC in the Massachusetts District Court over three patents covering 2′-fucosyllactose (2′-FL), a key human milk oligosaccharide ingredient. After 1,058 days of litigation and with Abbott Laboratories drawn in as a counterclaim-defendant, all parties settled with prejudice, each bearing their own costs and waiving any right to appeal.
HMO biosynthesis battle between two 2′-FL producers ends in mutual standdown
Chr. Hansen HMO GmbH, a German subsidiary within one of the world’s leading producers of human milk oligosaccharides, filed this declaratory judgment action on 7 July 2022 in the Massachusetts District Court. The dispute targeted three US patents held by Glycosyn LLC — US7521212B1, US9453230B2, and US9970018B2 — all relating to the biosynthesis of 2′-fucosyllactose (2′-FL), a commercially significant HMO widely used in infant formula and nutritional supplements.
The case closed on 30 May 2025 via a stipulated dismissal under Federal Rule of Civil Procedure 41(a)(1)(A)(ii). Crucially, all claims — Chr. Hansen’s declaratory claims against Glycosyn and Glycosyn’s counterclaims against both Chr. Hansen and Abbott Laboratories — were dismissed with prejudice. Each party agreed to bear its own costs and expressly waived any right to appeal, signalling a negotiated commercial resolution rather than a litigation victory for either side.
At nearly three years, the duration reflects the complexity typical of multi-patent biotech disputes, particularly where downstream commercial partners (here, Abbott Laboratories) become entangled as counterclaim-defendants. The with-prejudice dismissal and mutual appeal waiver suggest the settlement involves substantive licensing or coexistence terms — though the specific financial or licensing arrangements remain confidential from the public record. What drove the parties to resolve rather than proceed to claim construction or trial is not disclosed.
Filing to Dismissed with Prejudice in 1058 days
1,058 days — nearly three years, consistent with complex biotech patent disputes before trial
Settled with prejudice: what the stipulated dismissal means for both parties
Rule 41(a)(1)(A)(ii) stipulated dismissal with prejudice explained
A dismissal under FRCP 41(a)(1)(A)(ii) requires agreement from all parties who have appeared in the case. ‘With prejudice’ means neither Chr. Hansen nor Glycosyn can relitigate the same claims arising from these three patents in a new action. The dismissal has the force of a final adjudication on the merits for res judicata purposes, even though no court judgment was entered on the substance of the dispute.
Res judicata effect appliesChr. Hansen exits litigation — but with permanent claim closure
Chr. Hansen initiated this action seeking a declaration — likely of non-infringement or invalidity — against Glycosyn’s three HMO patents. The with-prejudice settlement bars Chr. Hansen from re-filing declaratory claims on these patents. This outcome is consistent with a commercial resolution, potentially including a licensing arrangement or freedom-to-operate agreement, though no such terms are disclosed in the public record.
Declaratory claims extinguishedGlycosyn’s counterclaims against Chr. Hansen and Abbott dismissed with prejudice
Glycosyn’s counterclaims — which extended to Abbott Laboratories as a counterclaim-defendant — are also permanently closed. Glycosyn cannot pursue infringement claims against Chr. Hansen or Abbott on these patents through future litigation arising from the same disputes. The mutual appeal waiver reinforces finality. Whether Glycosyn secured royalties or other commercial consideration is not publicly disclosed.
Counterclaims against Abbott also closedMutual standdown signals competitive coexistence in the 2′-FL market
The involvement of Abbott Laboratories — a major infant formula manufacturer and likely Chr. Hansen customer — elevated the commercial stakes substantially. A with-prejudice settlement with mutual appeal waivers across all three parties suggests the parties prioritised supply-chain certainty over continued litigation risk. For other 2′-FL producers and HMO ingredient suppliers, the scope of Glycosyn’s three patents remains untested by any court ruling, preserving uncertainty in this competitive sector.
Patent scope remains untestedFull party and counsel information
| Role | Name | Type | Detail |
|---|---|---|---|
| Plaintiff | Chr. Hansen Hmo, GmbH | Company | Human milk oligosaccharide producer — holder of 2′-FL HMO declaratory judgment claimsSearch in Eureka ↗ |
| Defendant | Glycosyn, LLC | Company | Glycosyn LLC — biotech firm and holder of three US 2′-FL HMO biosynthesis patentsSearch in Eureka ↗ |
| Plaintiff counsel | Allison M. Lucier | Attorney | Counsel for Chr. Hansen Hmo, GmbHSearch in Eureka ↗ |
| Plaintiff counsel | Anthony J. Fuga | Attorney | Counsel for Chr. Hansen Hmo, GmbHSearch in Eureka ↗ |
| Plaintiff counsel | Brian Murray | Attorney | Counsel for Chr. Hansen Hmo, GmbHSearch in Eureka ↗ |
| Plaintiff counsel | Bryan C. Nese | Attorney | Counsel for Chr. Hansen Hmo, GmbHSearch in Eureka ↗ |
| Plaintiff counsel | Dave Donoghue | Attorney | Counsel for Chr. Hansen Hmo, GmbHSearch in Eureka ↗ |
| Plaintiff counsel | Emily A. Robey-Phillips | Attorney | Counsel for Chr. Hansen Hmo, GmbHSearch in Eureka ↗ |
| Plaintiff counsel | Gary M. Hnath | Attorney | Counsel for Chr. Hansen Hmo, GmbHSearch in Eureka ↗ |
| Plaintiff counsel | James M. Campbell | Attorney | Counsel for Chr. Hansen Hmo, GmbHSearch in Eureka ↗ |
| Plaintiff counsel | Joshua C. Krumholz | Attorney | Counsel for Chr. Hansen Hmo, GmbHSearch in Eureka ↗ |
| Plaintiff counsel | Morgan Delabar | Attorney | Counsel for Chr. Hansen Hmo, GmbHSearch in Eureka ↗ |
| Plaintiff counsel | Robert David Donoghue | Attorney | Counsel for Chr. Hansen Hmo, GmbHSearch in Eureka ↗ |
| Plaintiff counsel | Ryan T. Babcock | Attorney | Counsel for Chr. Hansen Hmo, GmbHSearch in Eureka ↗ |
| Plaintiff counsel | Sadie Mlika | Attorney | Counsel for Chr. Hansen Hmo, GmbHSearch in Eureka ↗ |
| Plaintiff counsel | Scott A. McMurry | Attorney | Counsel for Chr. Hansen Hmo, GmbHSearch in Eureka ↗ |
| Plaintiff counsel | Tiffany Lee | Attorney | Counsel for Chr. Hansen Hmo, GmbHSearch in Eureka ↗ |
| Plaintiff counsel | Trevor J. Keenan | Attorney | Counsel for Chr. Hansen Hmo, GmbHSearch in Eureka ↗ |
| Plaintiff counsel | William Howard Oliver , III | Attorney | Counsel for Chr. Hansen Hmo, GmbHSearch in Eureka ↗ |
| Plaintiff law firm | Campbell Conroy & O’Neil, P.C. | Law Firm | Representing Chr. Hansen Hmo, GmbHSearch in Eureka ↗ |
| Plaintiff law firm | Holland & Knight LLP | Law Firm | Representing Chr. Hansen Hmo, GmbHSearch in Eureka ↗ |
| Plaintiff law firm | Mayer Brown LLP | Law Firm | Representing Chr. Hansen Hmo, GmbHSearch in Eureka ↗ |
| Defendant counsel | Amanda Metell | Attorney | Counsel for Glycosyn, LLCSearch in Eureka ↗ |
| Defendant counsel | Courtney Patrice Herndon | Attorney | Counsel for Glycosyn, LLCSearch in Eureka ↗ |
| Defendant counsel | James M. Wodarski | Attorney | Counsel for Glycosyn, LLCSearch in Eureka ↗ |
| Defendant counsel | Michael C. Newman | Attorney | Counsel for Glycosyn, LLCSearch in Eureka ↗ |
| Defendant counsel | Michael T. Renaud | Attorney | Counsel for Glycosyn, LLCSearch in Eureka ↗ |
| Defendant counsel | Nana Liu | Attorney | Counsel for Glycosyn, LLCSearch in Eureka ↗ |
| Defendant counsel | Paul Weinand | Attorney | Counsel for Glycosyn, LLCSearch in Eureka ↗ |
| Defendant counsel | Peter J. Cuomo | Attorney | Counsel for Glycosyn, LLCSearch in Eureka ↗ |
| Defendant counsel | Simone Yhap | Attorney | Counsel for Glycosyn, LLCSearch in Eureka ↗ |
| Defendant counsel | Thomas H. Wintner | Attorney | Counsel for Glycosyn, LLCSearch in Eureka ↗ |
| Defendant counsel | Williams Dixon | Attorney | Counsel for Glycosyn, LLCSearch in Eureka ↗ |
| Defendant law firm | Mintz, Levin, Cohn, Ferris, Glovsky & Popeo PC | Law Firm | Representing Glycosyn, LLCSearch in Eureka ↗ |
| Presiding judge | Judge Nathaniel M. Gorton | Judge | Massachusetts District CourtSearch in Eureka ↗ |
Official order — verbatim text
The stipulated dismissal under Rule 41(a)(1)(A)(ii) was filed jointly by Chr. Hansen, Glycosyn, and Abbott Laboratories, confirming a tripartite settlement. The with-prejudice designation is legally significant: it forecloses all three parties from relitigating the same patent claims, providing the functional equivalent of a final judgment without any court ruling on merits. The explicit appeal waiver — unusual in its breadth — further signals that all parties viewed the negotiated outcome as definitive. The public record is silent on financial terms, royalty rates, or any licensing arrangement that may underpin this resolution.
US7521212B1, US9453230B2 & US9970018B2 — 2′-FL HMO biosynthesis patents
The three patents at issue — US7521212B1, US9453230B2, and US9970018B2 — form a portfolio covering the biological synthesis of 2′-fucosyllactose (2′-FL), the most abundant oligosaccharide in human breast milk. Held by Glycosyn LLC, these patents span application dates ranging from the mid-2000s through the mid-2010s, reflecting successive innovation layers in microbial fermentation, strain engineering, and production optimisation for HMO manufacturing. The patents are foundational to the commercial-scale production of synthetic 2′-FL used in infant formula and functional nutrition products.
As 2′-FL has become a priority ingredient in premium infant formula globally — and as regulatory approvals have expanded in the EU, US, and Asia — the commercial value of these biosynthesis patents has grown substantially. Glycosyn’s portfolio positions it as a potential tollgate for any producer seeking to manufacture or supply 2′-FL using covered fermentation routes. Chr. Hansen, itself a major 2′-FL producer, and its customer Abbott represent exactly the commercial targets these patents are structured to reach. The untested validity of this portfolio post-settlement continues to create uncertainty for the broader HMO ingredient market.
Should your R&D team run an FTO against Glycosyn’s 2′-FL patent portfolio?
Any company developing, manufacturing, or sourcing 2′-fucosyllactose (2′-FL) for infant formula, dietary supplements, or clinical nutrition should treat Glycosyn’s three-patent portfolio as a material FTO risk. The Chr. Hansen v. Glycosyn settlement — which extended to downstream customer Abbott Laboratories — confirms that Glycosyn is willing to assert these patents against both ingredient producers and end-product brands. No claim construction order or invalidity ruling has narrowed the effective scope of these patents.
PatSnap Eureka’s FTO Search Agent can map your 2′-FL production process against the claim landscapes of US7521212B1, US9453230B2, and US9970018B2, identify potential design-around opportunities, and flag any related continuation or family members that may extend Glycosyn’s coverage. Eureka’s citation analytics can also surface prior art that was not raised in this litigation — useful context for any future IPR petition or licensing negotiation.
Run a freedom-to-operate analysis on US7521212B1 to assess your product’s exposure
Run FTO in Eureka →Similar HMO biosynthesis patent disputes in US federal courts
Explore related 2′-FL and human milk oligosaccharide patent cases filed in Massachusetts and other US district courts involving HMO biosynthesis technology.
What this case signals for the human milk oligosaccharide IP landscape
Three HMO biosynthesis patents, two major producers, and a global infant nutrition partner — the Chr. Hansen v. Glycosyn settlement has sector-wide implications.
Glycosyn’s three 2′-FL patents remain valid and untested by any court
Because the case settled before any claim construction or invalidity ruling, Glycosyn’s patents US7521212B1, US9453230B2, and US9970018B2 retain full presumptive validity. Any other 2′-FL producer operating in this space — particularly those supplying infant formula brands — should treat these patents as live enforcement risk. An FTO analysis against all three is advisable.
Abbott’s role as counterclaim-defendant signals supply-chain patent exposure
Glycosyn’s decision to counterclaim against Abbott Laboratories, a downstream customer of Chr. Hansen, is a reminder that HMO patent holders may pursue end-users and brand owners — not just ingredient manufacturers. Infant formula companies and nutritional supplement brands sourcing 2′-FL should review their indemnification provisions and supply agreements in light of this litigation pattern.
Chr. v Glycosyn — key questions answered
Three US patents held by Glycosyn LLC were at issue: US7521212B1, US9453230B2, and US9970018B2. All three cover aspects of the microbial biosynthesis of 2′-fucosyllactose (2′-FL), the primary human milk oligosaccharide used in commercial infant formula and nutritional supplement applications.
Abbott Laboratories was named as a counterclaim-defendant by Glycosyn LLC. Abbott is a major infant formula manufacturer and is widely understood to be a commercial customer of Chr. Hansen’s 2′-FL ingredient. Patent holders frequently pursue downstream brand owners and retailers in addition to ingredient suppliers to maximise commercial leverage and damages exposure.
A dismissal with prejudice under FRCP 41(a)(1)(A)(ii) means that all claims — Chr. Hansen’s declaratory judgment claims against Glycosyn and Glycosyn’s counterclaims against Chr. Hansen and Abbott — are permanently closed. No party can refile the same claims in a new action. It carries the legal effect of a final judgment on the merits for res judicata purposes, even though no court ruled on the substance of the dispute.
No. The case settled via stipulated dismissal before any claim construction order or merits ruling was entered. Glycosyn’s three patents — US7521212B1, US9453230B2, and US9970018B2 — retain their presumptive validity and have never been adjudicated by any court as to scope, validity, or infringement in this proceeding.
2′-fucosyllactose (2′-FL) is the most abundant oligosaccharide in human breast milk and has been approved as a food ingredient in infant formula across the EU, US, and major Asian markets. Its commercial value in the premium infant nutrition sector — estimated at hundreds of millions of dollars globally — makes biosynthesis patents covering its production highly valuable and increasingly contested among a small number of specialised biotech producers including Chr. Hansen and Glycosyn.
PatSnap Eureka searches patents and litigation data to answer instantly.